Novel targeted treatment options for advanced cholangiocarcinoma.
Amit MahipalAnuhya KommalapatiSri Harsha TellaAlexander LimRichard KimPublished in: Expert opinion on investigational drugs (2018)
Advanced cholangiocarcinoma has a dismal prognosis; improved understanding of the molecular pathogenesis and advancements in development of targeted therapy offers hope that we may improve outcomes in this rare, but highly lethal cancer. Among the newly discovered molecular alterations, targeting FGFR2 fusions, IDH1/2 mutations and HER2 receptors hold great promise for improving the future management of cholangiocarcinoma. Immunotherapy in combination with targeted agents and chemotherapy may improve outcomes. In addition, drugs targeting the MEK, EGFR, KRAS, BRAF, and ROS1 pathways and neo-angiogenesis may also provide new horizons in the management of cholangiocarcinoma.
Keyphrases
- cancer therapy
- small cell lung cancer
- wild type
- cell death
- drug delivery
- endothelial cells
- pi k akt
- single molecule
- epidermal growth factor receptor
- metabolic syndrome
- radiation therapy
- signaling pathway
- rectal cancer
- deep learning
- cell proliferation
- reactive oxygen species
- adipose tissue
- insulin resistance
- skeletal muscle
- artificial intelligence
- glycemic control